United Kingdom

People: Alpine Immune Sciences Inc (ALPN.OQ)

ALPN.OQ on NASDAQ Stock Exchange Global Market

22 Aug 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Peng, Stanford 

Dr. Stanford Peng M.D. Ph.D. is President and Head of Research and Development of the company. he was serves as Executive Vice President - Research and Development, Chief Medical Officer of the company. He has as served as our executive vice president of research and development and chief medical officer since the completion of the Merger in July 2017 and previously served as Private Alpine’s chief medical officer From September 2016 to February 2017 and as Private Alpine’s executive vice president of research and development and chief medical officer since February 2017. Prior to joining Private Alpine, Dr. Peng was chief medical officer and head of clinical development at Stemcentrx, providing strategic oversight of the company’s clinical and translational programs from 2015 to 2016. Previously, Dr. Peng was executive medical director at Seattle Genetics where he developed multiple programs for antibody-drug conjugates from 2014 to 2015. Earlier in his career, he directed translational research and auto-immune related clinical trials as head of the Rheumatology Clinical Research Unit at the Benaroya Research Institute from 2009 to 2014 and served as senior director, clinical research and exploratory development at Roche from 2005 to 2008. Between 2009 and 2014, Dr. Peng also served as member physician at Virginia Mason Medical Center. Dr. Peng served as an assistant professor at the Washington University School of Medicine from 2002 to 2005. From 2008 to 2009, Dr. Peng served as senior director at ARYx Therapeutics, Inc. (Nasdaq: ARYX). Dr. Peng received an M.D. and Ph.D. in biology from the Yale University School of Medicine and a B.A. in music and B.S. in biological sciences from Stanford University.

Basic Compensation

Total Annual Compensation, USD 375,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 171,010
Fiscal Year Total, USD 546,010

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --